Immersive Virtual Reality for the Non-pharmacological Management of Parkinson's Disease

Campus Neurológico Sénior30 enrolled

Overview

The goal of this clinical trial is to evaluate the feasibility, safety and efficacy of an immersive virtual reality (IVR) exergaming using a head-mounted display in Parkinson's disease symptomatic control. This is a parallel-group, single-blinded, randomized controlled trial. The intervention group perform 12 weeks of physiotherapy and IVR, whereas the control group have 6 weeks of physiotherapy only, followed by 6 weeks of physiotherapy and IVR. The primary outcome is the symptomatic effect of the intervention as measured by the change from baseline in Time Up and Go (TUG) test with cognitive dual-task (TUG cognitive).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Parkinson Disease

Interventions

A commercially available head-mounted display. Each VR session has approximately 20 minutes, performed 3 times per week. Both groups maintain similar PD specialized physiotherapy sessions throughout the duration of the study (3 times per week, 60 minutes per session).

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients diagnosed with Parkinson's disease according to MDS criteria; * Hoehn and Yahr stages between I-III (MED ON); * Ability to perform the Time Up and Go test in normal pace and without assistance, in less than 11,5 seconds in ON state; * Stable medication for the past 1 month; * Ability to communicate with the investigator, to understand and comply with the requirements of the study; * Able to provide written informed consent to participate in the study. Exclusion Criteria: * Postural instability or freezing of gait in MED ON representing an increased risk of fall, according to the best clinical judgement; * A Montreal Cognitive Assessment (MoCA) score \< 21; * Presence of severe visual loss that could interfere with the ability to see the VR simulation as well as vertigo, epilepsy and psychosis; * Unstable medical condition, including cardiovascular, pulmonary or musculoskeletal, that according to the clinician's judgment affect patients' ability to participate in the study; * Inability to correctly respond to the assessment protocol according to the clinician's judgment or lack of support from caregiver for this effect.

Outcomes

Primary Outcomes

Change from baseline to 6-week in TUG cognitive test

Time frame: 6 week

Secondary Outcomes

Change from baseline to each evaluation time point in TUG and TUG with motor and cognitive dual-tasking

Difference between groups in change from baseline to each evaluation time point in TUG and TUG with motor and cognitive dual-tasking